文章摘要
新冠肺炎防治技术专利情报分析研究
Intelligence Analysis of COVID-19 Prevention and Treatment Technology Patents
投稿时间:2020-03-24  修订日期:2020-12-31
DOI:
中文关键词: 新冠肺炎  发明专利  情报分析
英文关键词: COVID-19  Invention patents  Intelligence analysis
基金项目:南京市医学科技发展资金资助项目(YKK18082,QRX17145)
作者单位邮编
周爱平 南京鼓楼医院 210008
张语馨 南京鼓楼医院 
王健 南京鼓楼医院 
龚跃鹏 江苏省专利信息服务中心 
薛倩 江苏省专利信息服务中心 
王亚利 江苏省专利信息服务中心 210008
摘要点击次数: 42
中文摘要:
      目的:本研究对全球103个国家或地区新冠肺炎防治技术的发明专利情况进行分析,了解全球新冠肺炎防治技术研发的最新研究动态,探讨新冠肺炎防治技术的研发方向,为跨学科、多团队合作提供理论依据。方法:结合国家知识产权局区域专利信息服务(南京)中心检索与分析系统和IncoPat科技创新情报共同构建检索策略,以三级分支为单位,分开检索论证,检索式运用IPC分类号加关键词限定;专利类型限定为发明专利,不包括实用新型和外观设计,数据截至2020年2月14日。结果:截至2020年2月14日,全球新冠肺炎防治技术发明专利共申请136087件;从申请来源国来看,美国共56095件位居榜首,排名第二是中国18096件;从技术领域来看,排名前三的分别是化学治疗药物(47634件)、疫苗(47248件)和诊断检测(12991件),美国在以上三个技术领域的专利布局都有绝对优势;从专利申请人来看,国外的主要集中在大型的企业,中国主要分布在高校和科研院所。结论与建议:我国新冠肺炎相关专利申请较为分散,在化学治疗领域与世界领先国家存在一定差距,在疫苗研发领域与世界领先国家差距逐渐缩小。因此,我国应进一步加大化学药物研发的投入以及抓住时机积极推动疫苗技术的研发;另一方面巩固已经积累的流行性疾病防治的相关技术优势和产品优势,加强知识产权的保护和布局;再者以产学研结合的技术创新体系为突破口鼓励企业成为技术创新主体;最后搭建科技成果转移转化服务平台,提升知识产权能力,促进科技成果转化。
英文摘要:
      Objective: This study analyzes Coronavirus Disease 2019 (COVID-19) prevention and treatment technology patents from 103 countries and regions worldwide, in order to have a good grasp of the latest trends in COVID-19 prevention and treatment technology research worldwide, discuss the research directions of such technologies, and provide theoretical foundations for interdisciplinary and multi-team cooperations. Methods: The retrieval strategies were constructed utilizing the retrieval and analysis system by the Regional Patent Information Service (Nanjing) Center of The State Intellectual Property Office and IncoPat's scientific and technological innovation platform, using third-level branches as the unit and separating the retrieval and proof processes, the queries built using IPC classification numbers and key words; the search was limited to invention patents, with utility models and designs excluded. Data up to February 14, 2020 were used. Results: As of February 14, 2020, there had been a total of 136,087 invention patent applications for COVID-19 prevention and treatment technologies globally. In terms of the country of origin, the US ranked first with 56,095 patents, followed by China (18,096). In terms of technical field, the top three were chemical therapeutic agents (47,634), vaccines (47,248), and diagnostic tests (12,991), with the US possessing absolutely advantageous patent portfolios in all three fields. The applicants were mainly comprised of large enterprises abroad and universities and research institutes in China. Conclusions: China's COVID-19 related patent applications are relatively scattered. In the field of chemotherapy, there is room for improvement compared with the advanced countries, but in vaccine research and development we are gradually catching up. Therefore, China should further increase investment in chemical drug research and development and seize the opportunity to actively promote the research and development of vaccine technology; on the other hand, we need to consolidate the technical advantages and product advantages of epidemic prevention and control already accumulated, and strengthen the protection and layout of intellectual property rights; furthermore, the technological innovation system combining production, education and research is the breakthrough point to encourage enterprises to become the subject of technological innovation;last but not least,we should build a service platform for the transfer and transformation of scientific and technological achievements to enhance intellectual property rights and promote the transformation of scientific and technological achievements.
  查看/发表评论  下载PDF阅读器